JP2002502222A - Ｂ型肝炎表面抗原に対して活性なヒトモノクローナル抗体の生産 - Google Patents

Ｂ型肝炎表面抗原に対して活性なヒトモノクローナル抗体の生産

Info

Publication number
JP2002502222A
JP2002502222A JP51202994A JP51202994A JP2002502222A JP 2002502222 A JP2002502222 A JP 2002502222A JP 51202994 A JP51202994 A JP 51202994A JP 51202994 A JP51202994 A JP 51202994A JP 2002502222 A JP2002502222 A JP 2002502222A
Authority
JP
Japan
Prior art keywords
antibody
cell line
hepatitis
mixture
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP51202994A
Other languages
English (en)
Japanese (ja)
Inventor
オストバーグ、ラース、ジー．
Original Assignee
ノバーティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバーティス アクチエンゲゼルシャフト filed Critical ノバーティス アクチエンゲゼルシャフト
Priority claimed from PCT/US1992/009749 external-priority patent/WO1994011495A1/en
Publication of JP2002502222A publication Critical patent/JP2002502222A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP51202994A 1992-11-06 1992-11-06 Ｂ型肝炎表面抗原に対して活性なヒトモノクローナル抗体の生産 Ceased JP2002502222A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1992/009749 WO1994011495A1 (en) 1992-11-06 1992-11-06 Production of human monoclonal antibodies active against hepatitis b surface antigen

Publications (1)

Publication Number Publication Date
JP2002502222A true JP2002502222A (ja) 2002-01-22

Family

ID=22231529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51202994A Ceased JP2002502222A (ja) 1992-11-06 1992-11-06 Ｂ型肝炎表面抗原に対して活性なヒトモノクローナル抗体の生産

Country Status (5)

Country Link
JP (1) JP2002502222A (de)
KR (1) KR100281163B1 (de)
AT (1) ATE207119T1 (de)
DE (1) DE69232140D1 (de)
RU (1) RU2146706C1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525071A (ja) * 2018-05-31 2021-09-24 ノバルティス アーゲー Ｂ型肝炎抗体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3298038B1 (de) * 2015-05-22 2021-08-04 Huahui Health Ltd. Anti-pre-s1-hbv-antikörper
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
AU2018350693B2 (en) * 2017-10-16 2021-03-04 F. Hoffmann-La Roche Ag Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525071A (ja) * 2018-05-31 2021-09-24 ノバルティス アーゲー Ｂ型肝炎抗体
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
JP7490574B2 (ja) 2018-05-31 2024-05-27 ノバルティス アーゲー Ｂ型肝炎抗体

Also Published As

Publication number Publication date
KR100281163B1 (ko) 2001-04-02
RU95117092A (ru) 1997-03-27
RU2146706C1 (ru) 2000-03-20
ATE207119T1 (de) 2001-11-15
DE69232140D1 (de) 2001-11-22
KR950704478A (ko) 1995-11-20

Similar Documents

Publication Publication Date Title
US5565354A (en) Production of human monoclonal antibodies specific for hepatitis B surface antigen
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
US5698419A (en) Monoclonal antibodies to cachectin/tumor necrosis factor and methods for preparing same
JPH06506120A (ja) ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体
JPH02500085A (ja) 血小板の粘着を阻害するペプチド及び抗体
JPH034781A (ja) 肝炎ウイルス抗体を産生する細胞系
KR20210005169A (ko) 최적화된 항tl1a 항체
WO2016173558A1 (zh) 抗诺如病毒gii.4型鼠源单克隆抗体的制备和应用
JPH02295487A (ja) キメラモノクローナル抗体の産生のための発現系
JPH10130167A (ja) 補体成分Ｃ５ａに対するモノクローナル抗体
KR101589135B1 (ko) 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
JPH08501925A (ja) 糖蛋白ｐに対するモノクローナル抗体
AU2021209746A1 (en) Anti-ANGPTL3 antibody and use thereof
JPH05260990A (ja) モノクローナル抗体
JP2618618B2 (ja) 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
JPH08506325A (ja) サイトメガロウイルスに対するヒトモノクローナル抗体
AU684455B2 (en) Production of human monoclonal antibodies active against hepatitis B surface antigen
JP2002502222A (ja) Ｂ型肝炎表面抗原に対して活性なヒトモノクローナル抗体の生産
JP2001509020A (ja) ラミニンのニドゲン結合ドメインに結合する抗体、その調製および使用
JP4044733B2 (ja) ベロ毒素ｉｉを認識するヒト型化抗体、および該抗体を産生する細胞株
EP0672120B1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
JPH08510635A (ja) Ｂ型肝炎エスケープミュータント特異的結合分子
CN114920842B (zh) 特异性结合pv-1蛋白的抗体或其抗原结合片段及其应用
JPH06503002A (ja) ストレプトリシンｏ誘導体及び変異体の抗体
JP4361579B2 (ja) コンドロイチナーゼａｂｃに対するモノクローナル抗体

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040120

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040225

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040511

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20041101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041025

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050607

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20051025